{
  "guideline": {
    "id": "PA166104951",
    "name": "Annotation of DPWG Guideline for irinotecan and UGT1A1",
    "source": "DPWG",
    "version": 36,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104951",
    "relatedChemicals": [
      {
        "id": "PA450085",
        "name": "irinotecan",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA420",
        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
        "symbol": "UGT1A1"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299190",
      "name": "Recommendation PA166299190",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061553,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "This genetic variation (IM) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful."
      ],
      "lookupKey": {
        "UGT1A1": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166303201",
      "name": "Recommendation Annotation PA166303201",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452108720,
        "html": "<p>Start with 70% of the normal dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.</p>\n<p><em>The normal dose is defined as the dose the patient would receive if he/she would not have a gene variant.</em></p>\n"
      },
      "implications": [
        "Serious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites."
      ],
      "lookupKey": {
        "UGT1A1": {
          "*28": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299189",
      "name": "Recommendation PA166299189",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061552,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "This genetic variation (*1/*28) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful. Note that DPWG considers the *36 allele to be clinically equivalent to the *1 allele."
      ],
      "lookupKey": {
        "UGT1A1": {
          "*1": 1.0,
          "*28": 1.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299188",
      "name": "Recommendation PA166299188",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061551,
        "html": "<p>The guideline does not provide a recommendation for irinotecan in normal metabolizers</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on irinotecan."
      ],
      "lookupKey": {
        "UGT1A1": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299191",
      "name": "Recommendation PA166299191",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061554,
        "html": "<p>Start with 70% of the normal dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.</p>\n<p><em>The normal dose is defined as the dose the patient would receive if he/she would not have a gene variant.</em></p>\n"
      },
      "implications": [
        "Serious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites."
      ],
      "lookupKey": {
        "UGT1A1": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166313042",
      "name": "Recommendation Annotation PA166313042",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452221721,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "This genetic variation (*1/*28) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful. Note that DPWG considers the *36 allele to be clinically equivalent to the *1 allele."
      ],
      "lookupKey": {
        "UGT1A1": {
          "*1": 1.0,
          "*80+*28": 1.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166313041",
      "name": "Recommendation Annotation PA166313041",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452221720,
        "html": "<p>Start with 70% of the normal dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.</p>\n<p><em>The normal dose is defined as the dose the patient would receive if he/she would not have a gene variant.</em></p>\n"
      },
      "implications": [
        "Serious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites."
      ],
      "lookupKey": {
        "UGT1A1": {
          "*80+*28": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "36443464",
      "title": "Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.",
      "authors": [
        "Hulshof Emma C",
        "Deenen Maarten J",
        "Nijenhuis Marga",
        "Soree Bianca",
        "de Boer-Veger Nienke J",
        "Buunk Anne-Marie",
        "Houwink Elisa J F",
        "Risselada Arne",
        "Rongen Gerard A P J M",
        "van Schaik Ron H N",
        "Touw Daan J",
        "van der Weide Jan",
        "van Westrhenen Roos",
        "Deneer Vera H M",
        "Guchelaar Henk-Jan",
        "Swen Jesse J"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2023,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474017"
    },
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
    }
  ],
  "version": "2024-02-29-20-19"
}